Skip to main content
Tourmaline Bio, Inc. logo

Tourmaline Bio, Inc. — Investor Relations & Filings

Ticker · TRML ISIN · US87410C1045 US Manufacturing
Filings indexed 336 across all filing types
Latest filing 2025-11-17 Regulatory Filings
Country US United States of America
Listing US TRML

About Tourmaline Bio, Inc.

https://www.tourmalinebio.com/

Tourmaline Bio, Inc. is a late-stage clinical biotechnology company focused on developing transformative medicines for patients with life-altering inflammatory and immune diseases. The company's lead asset is pacibekitug, a monoclonal antibody that targets the interleukin-6 (IL-6) cytokine, a key driver of inflammation. Pacibekitug is being developed as a potential treatment for a range of conditions, with a primary focus on atherosclerotic cardiovascular disease (ASCVD) and other severe autoimmune and inflammatory disorders, aiming to establish a new standard of care in areas with high unmet medical need.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2025
Regulatory Filings
2025-11-17 English
Regulatory Filings 2025
Regulatory Filings
2025-11-17 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-14 English
FORM 15-12G
Regulatory Filings
2025-11-07 English
Director's Dealing 2025
Director's Dealing
2025-10-28 English
Director's Dealing 2025
Director's Dealing
2025-10-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.